In a JAMA Viewpoint, Dr. Collins and Johnson & Johnson’s Dr. Paul Stoffels describe the direction of the ACTIV public-private partnership to address the COVID-19 pandemic | National Institutes of Health (NIH)

In a JAMA Viewpoint, Dr. Collins and Johnson & Johnson’s Dr. Paul Stoffels describe the direction of the ACTIV public-private partnership to address the COVID-19 pandemic | National Institutes of Health (NIH)

In a JAMA Viewpoint, Dr. Collins and Johnson & Johnson’s Dr. Paul Stoffels describe the direction of the ACTIV public-private partnership to address the COVID-19 pandemic

The paper details the goals of the ACTIV partnership’s four working groups, which together aim to establish a collaborative framework to prioritize therapeutic and vaccine candidates and streamline human clinical trials. JAMA: Online: May 18, 2020.

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.8920(link is external)

This page last reviewed on May 18, 2020